ArticleScientific reports2026
Elucidating the anti-colorectal cancer mechanism of Physalis Calyx seu Fructus extract via mass spectrometry-molecular networking and bioinformatics.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chemical profiling combined with computational analysis highlighted luteolin and chrysoeriol as candidate anti-colorectal cancer (CRC) compounds in Physalis Calyx seu Fructus (PCF) extract, potentially associated with MMP9 and CDK1. Ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF-MS) generated 23 annotated MS entries from PCF extracts, while bioinformatics analysis of Gene Expression Omnibus (GEO) datasets revealed 867 CRC-dysregulated genes. Weighted gene co-expression network analysis (WGCNA) and machine learning prioritized 397 core CRC genes enriched in cell cycle regulation, with CDK1 and MMP9 as top hubs. Network pharmacology mapped PCF-related compounds to 468 CRC targets, identifying 25 overlapping targets with core genes. Molecular docking showed that the putatively annotated compounds luteolin and chrysoeriol exhibited favorable binding to MMP9 and CDK1, respectively. 100-ns molecular dynamics (MD) simulations suggested structural stability for both complexes (RMSD: 2.7-2.8 Å). These findings suggest that luteolin- and chrysoeriol-related features may contribute to the anti-CRC potential of PCF by affecting cell-cycle-associated targets, although further experimental validation is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.